Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics

Alon Harris, M. Zalish, L. Kagemann, Brent Siesky, R. Migliardi, H. J. Garzozi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose. Topically-applied dopamine antagonists reduce intraocular pressure (IOP) and increase retinal blood flow in animal models. We examined the acute effects of intravenous infusion of a dopamine blocker (droperidol) on these parameters in healthy humans. Methods. Sixteen subjects free from ocular or systemic disease (mean age 33 ± 10 yrs) received either 5 mg iv droperidol over 5 minutes, or iv saline placebo in double-masked fashion. IOP was determined 30 and 60 minutes later, while color Doppler imaging was used to determine flow velocities in the ophthalmic, central retinal, and nasal and temporal posterior ciliary arteries 60 minutes after drug infusion. Results. 30 minutes after drug infusion, IOP was reduced 6.0 mmHg as compared with baseline (p<0.001); after 60 minutes, IOP remained reduced by 3.7 mmHg (p<0.00 1). Placebo had no effect on IOP. While droperidol slightly elevated blood pressure and increased the calculated ocular perfusion pressure, the drug reduced visual acuity and contrast sensitivity (p<0.05). Droperidol elevated peak systolic velocity in the central retinal and nasal posterior ciliary arteries, without changing end-diastolic velocity or the resistance index in either of these vessels. Droperidol had no effect on flow velocities in the ophthalmic artery or the temporal posterior ciliary artery. Conclusions. The rapid and marked ocular hypotension resulting from intravenous droperidol suggests that this agent may prove useful in the management of acute ocular hypertension. The retrobulbar changes consequent to the ocular tension reduction likely represent autoregulatory responses to altered ocular perfusion pressure.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalEuropean Journal of Ophthalmology
Volume12
Issue number3
StatePublished - 2002

Fingerprint

Droperidol
Intraocular Pressure
Hemodynamics
Ciliary Arteries
Dopamine Antagonists
Nose
Ocular Hypotension
Perfusion
Placebos
Pharmaceutical Preparations
Ophthalmic Artery
Pressure
Ocular Hypertension
Contrast Sensitivity
Intravenous Infusions
Visual Acuity
Animal Models
Color
Blood Pressure

Keywords

  • Dopamine antagonist
  • Intraocular pressure
  • Ocular blood flow

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics. / Harris, Alon; Zalish, M.; Kagemann, L.; Siesky, Brent; Migliardi, R.; Garzozi, H. J.

In: European Journal of Ophthalmology, Vol. 12, No. 3, 2002, p. 193-199.

Research output: Contribution to journalArticle

Harris, A, Zalish, M, Kagemann, L, Siesky, B, Migliardi, R & Garzozi, HJ 2002, 'Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics', European Journal of Ophthalmology, vol. 12, no. 3, pp. 193-199.
Harris, Alon ; Zalish, M. ; Kagemann, L. ; Siesky, Brent ; Migliardi, R. ; Garzozi, H. J. / Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics. In: European Journal of Ophthalmology. 2002 ; Vol. 12, No. 3. pp. 193-199.
@article{a33335015ff04105b7fbfb7a048cc92c,
title = "Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics",
abstract = "Purpose. Topically-applied dopamine antagonists reduce intraocular pressure (IOP) and increase retinal blood flow in animal models. We examined the acute effects of intravenous infusion of a dopamine blocker (droperidol) on these parameters in healthy humans. Methods. Sixteen subjects free from ocular or systemic disease (mean age 33 ± 10 yrs) received either 5 mg iv droperidol over 5 minutes, or iv saline placebo in double-masked fashion. IOP was determined 30 and 60 minutes later, while color Doppler imaging was used to determine flow velocities in the ophthalmic, central retinal, and nasal and temporal posterior ciliary arteries 60 minutes after drug infusion. Results. 30 minutes after drug infusion, IOP was reduced 6.0 mmHg as compared with baseline (p<0.001); after 60 minutes, IOP remained reduced by 3.7 mmHg (p<0.00 1). Placebo had no effect on IOP. While droperidol slightly elevated blood pressure and increased the calculated ocular perfusion pressure, the drug reduced visual acuity and contrast sensitivity (p<0.05). Droperidol elevated peak systolic velocity in the central retinal and nasal posterior ciliary arteries, without changing end-diastolic velocity or the resistance index in either of these vessels. Droperidol had no effect on flow velocities in the ophthalmic artery or the temporal posterior ciliary artery. Conclusions. The rapid and marked ocular hypotension resulting from intravenous droperidol suggests that this agent may prove useful in the management of acute ocular hypertension. The retrobulbar changes consequent to the ocular tension reduction likely represent autoregulatory responses to altered ocular perfusion pressure.",
keywords = "Dopamine antagonist, Intraocular pressure, Ocular blood flow",
author = "Alon Harris and M. Zalish and L. Kagemann and Brent Siesky and R. Migliardi and Garzozi, {H. J.}",
year = "2002",
language = "English",
volume = "12",
pages = "193--199",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "3",

}

TY - JOUR

T1 - Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics

AU - Harris, Alon

AU - Zalish, M.

AU - Kagemann, L.

AU - Siesky, Brent

AU - Migliardi, R.

AU - Garzozi, H. J.

PY - 2002

Y1 - 2002

N2 - Purpose. Topically-applied dopamine antagonists reduce intraocular pressure (IOP) and increase retinal blood flow in animal models. We examined the acute effects of intravenous infusion of a dopamine blocker (droperidol) on these parameters in healthy humans. Methods. Sixteen subjects free from ocular or systemic disease (mean age 33 ± 10 yrs) received either 5 mg iv droperidol over 5 minutes, or iv saline placebo in double-masked fashion. IOP was determined 30 and 60 minutes later, while color Doppler imaging was used to determine flow velocities in the ophthalmic, central retinal, and nasal and temporal posterior ciliary arteries 60 minutes after drug infusion. Results. 30 minutes after drug infusion, IOP was reduced 6.0 mmHg as compared with baseline (p<0.001); after 60 minutes, IOP remained reduced by 3.7 mmHg (p<0.00 1). Placebo had no effect on IOP. While droperidol slightly elevated blood pressure and increased the calculated ocular perfusion pressure, the drug reduced visual acuity and contrast sensitivity (p<0.05). Droperidol elevated peak systolic velocity in the central retinal and nasal posterior ciliary arteries, without changing end-diastolic velocity or the resistance index in either of these vessels. Droperidol had no effect on flow velocities in the ophthalmic artery or the temporal posterior ciliary artery. Conclusions. The rapid and marked ocular hypotension resulting from intravenous droperidol suggests that this agent may prove useful in the management of acute ocular hypertension. The retrobulbar changes consequent to the ocular tension reduction likely represent autoregulatory responses to altered ocular perfusion pressure.

AB - Purpose. Topically-applied dopamine antagonists reduce intraocular pressure (IOP) and increase retinal blood flow in animal models. We examined the acute effects of intravenous infusion of a dopamine blocker (droperidol) on these parameters in healthy humans. Methods. Sixteen subjects free from ocular or systemic disease (mean age 33 ± 10 yrs) received either 5 mg iv droperidol over 5 minutes, or iv saline placebo in double-masked fashion. IOP was determined 30 and 60 minutes later, while color Doppler imaging was used to determine flow velocities in the ophthalmic, central retinal, and nasal and temporal posterior ciliary arteries 60 minutes after drug infusion. Results. 30 minutes after drug infusion, IOP was reduced 6.0 mmHg as compared with baseline (p<0.001); after 60 minutes, IOP remained reduced by 3.7 mmHg (p<0.00 1). Placebo had no effect on IOP. While droperidol slightly elevated blood pressure and increased the calculated ocular perfusion pressure, the drug reduced visual acuity and contrast sensitivity (p<0.05). Droperidol elevated peak systolic velocity in the central retinal and nasal posterior ciliary arteries, without changing end-diastolic velocity or the resistance index in either of these vessels. Droperidol had no effect on flow velocities in the ophthalmic artery or the temporal posterior ciliary artery. Conclusions. The rapid and marked ocular hypotension resulting from intravenous droperidol suggests that this agent may prove useful in the management of acute ocular hypertension. The retrobulbar changes consequent to the ocular tension reduction likely represent autoregulatory responses to altered ocular perfusion pressure.

KW - Dopamine antagonist

KW - Intraocular pressure

KW - Ocular blood flow

UR - http://www.scopus.com/inward/record.url?scp=0035987020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035987020&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 193

EP - 199

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

IS - 3

ER -